title: Author reply to: Hepatitis B reactivation in chronic hepatitis C patients during treatment with ledipasvir and sofosbuvir.
authors.affiliation: Auckland Clinical Studies, Auckland, New Zealand.|New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand.
authors.forename: Edward J
authors.initials: EJ
authors.lastname: Gane
authors.affiliation: Gilead Sciences, Inc., Foster City, CA, USA.
authors.forename: Robert H
authors.initials: RH
authors.lastname: Hyland
authors.affiliation: Gilead Sciences, Inc., Foster City, CA, USA.
authors.forename: Di
authors.initials: D
authors.lastname: An
authors.affiliation: Gilead Sciences, Inc., Foster City, CA, USA.
authors.forename: Evguenia S
authors.initials: ES
authors.lastname: Svarovskaia
authors.affiliation: Gilead Sciences, Inc., Foster City, CA, USA.
authors.forename: Diana
authors.initials: D
authors.lastname: Brainard
authors.affiliation: Gilead Sciences, Inc., Foster City, CA, USA.
authors.forename: John G
authors.initials: JG
authors.lastname: McHutchison
mesh_terms: D001562:Benzimidazoles; D060085:Coinfection; D005449:Fluorenes; D015658:HIV Infections; D006509:Hepatitis B; D006515:Hepatitis B virus; D019698:Hepatitis C, Chronic; D006801:Humans; D000069474:Sofosbuvir
chemical_list: D001562:Benzimidazoles; D005449:Fluorenes; C586541:ledipasvir; D000069474:Sofosbuvir